Exclusive Financial Advisor to Altor Bioscience Corporation^* on Sale of Preferred Stock

2005 — Completed the sale of Altor BioScience Corporation Series B-1 Preferred Stock to Sanderling, a leading biotech capital investor.

“Altor is very pleased with the results of this financing,” said Dr. Hing Wong, Altor’s Chief Executive Officer”.

*Altor Bioscience Corporation merged with NantCell in 2017 and subsequently went public as ImmunityBio